OA10535A - Complexes organométalliques du fer antipaludiques - Google Patents
Complexes organométalliques du fer antipaludiques Download PDFInfo
- Publication number
- OA10535A OA10535A OA70125A OA70125A OA10535A OA 10535 A OA10535 A OA 10535A OA 70125 A OA70125 A OA 70125A OA 70125 A OA70125 A OA 70125A OA 10535 A OA10535 A OA 10535A
- Authority
- OA
- OAPI
- Prior art keywords
- alkyl
- ferrocene
- hydrogen
- group
- complex according
- Prior art date
Links
- 230000000078 anti-malarial effect Effects 0.000 title claims abstract description 16
- 125000002524 organometallic group Chemical group 0.000 title claims description 14
- 239000003430 antimalarial agent Substances 0.000 title description 10
- 150000002505 iron Chemical class 0.000 title 1
- KTWOOEGAPBSYNW-UHFFFAOYSA-N ferrocene Chemical group [Fe+2].C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 KTWOOEGAPBSYNW-UHFFFAOYSA-N 0.000 claims abstract description 29
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical group [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims abstract description 26
- -1 Organometallic iron complexes Chemical class 0.000 claims abstract description 6
- 150000001875 compounds Chemical class 0.000 claims description 30
- 125000000217 alkyl group Chemical group 0.000 claims description 20
- 229910052739 hydrogen Inorganic materials 0.000 claims description 16
- 239000001257 hydrogen Substances 0.000 claims description 16
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 12
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 10
- 229940095064 tartrate Drugs 0.000 claims description 9
- 125000002252 acyl group Chemical group 0.000 claims description 8
- 125000005041 acyloxyalkyl group Chemical group 0.000 claims description 8
- 125000003545 alkoxy group Chemical group 0.000 claims description 8
- 229910052736 halogen Inorganic materials 0.000 claims description 8
- 150000002367 halogens Chemical group 0.000 claims description 8
- 201000004792 malaria Diseases 0.000 claims description 7
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 150000001412 amines Chemical group 0.000 claims description 5
- 238000011282 treatment Methods 0.000 claims description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 125000003277 amino group Chemical group 0.000 claims description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000005842 heteroatom Chemical group 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 3
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims 2
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims 1
- VSEAAEQOQBMPQF-UHFFFAOYSA-N morpholin-3-one Chemical compound O=C1COCCN1 VSEAAEQOQBMPQF-UHFFFAOYSA-N 0.000 claims 1
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 abstract description 10
- 235000001258 Cinchona calisaya Nutrition 0.000 abstract description 6
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 abstract description 5
- 229960000948 quinine Drugs 0.000 abstract description 5
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 15
- 229960003677 chloroquine Drugs 0.000 description 15
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 15
- 238000003786 synthesis reaction Methods 0.000 description 13
- 230000000694 effects Effects 0.000 description 10
- 229910052742 iron Inorganic materials 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 9
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 7
- 150000001299 aldehydes Chemical class 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 6
- 244000045947 parasite Species 0.000 description 6
- 125000001424 substituent group Chemical group 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 5
- 241000157855 Cinchona Species 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 238000006683 Mannich reaction Methods 0.000 description 4
- 241000224016 Plasmodium Species 0.000 description 4
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 4
- 238000009833 condensation Methods 0.000 description 4
- 230000005494 condensation Effects 0.000 description 4
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 4
- GPKJTRJOBQGKQK-UHFFFAOYSA-N quinacrine Chemical compound C1=C(OC)C=C2C(NC(C)CCCN(CC)CC)=C(C=CC(Cl)=C3)C3=NC2=C1 GPKJTRJOBQGKQK-UHFFFAOYSA-N 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 3
- 241000223830 Plasmodium yoelii Species 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 150000002466 imines Chemical class 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000006138 lithiation reaction Methods 0.000 description 3
- 229960000901 mepacrine Drugs 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- FQYRLEXKXQRZDH-UHFFFAOYSA-N 4-aminoquinoline Chemical compound C1=CC=C2C(N)=CC=NC2=C1 FQYRLEXKXQRZDH-UHFFFAOYSA-N 0.000 description 2
- 241000224017 Plasmodium berghei Species 0.000 description 2
- 241000223960 Plasmodium falciparum Species 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 229940033495 antimalarials Drugs 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- 125000004663 dialkyl amino group Chemical group 0.000 description 2
- 125000005265 dialkylamine group Chemical group 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 235000019256 formaldehyde Nutrition 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 229960005179 primaquine Drugs 0.000 description 2
- INDBQLZJXZLFIT-UHFFFAOYSA-N primaquine Chemical compound N1=CC=CC2=CC(OC)=CC(NC(C)CCCN)=C21 INDBQLZJXZLFIT-UHFFFAOYSA-N 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- MGCGJBXTNWUHQE-UHFFFAOYSA-N quinoline-4-carbaldehyde Chemical compound C1=CC=C2C(C=O)=CC=NC2=C1 MGCGJBXTNWUHQE-UHFFFAOYSA-N 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- KWVNKWCJDAWNAE-UHFFFAOYSA-N 2,3-dichloroquinoline Chemical compound C1=CC=C2N=C(Cl)C(Cl)=CC2=C1 KWVNKWCJDAWNAE-UHFFFAOYSA-N 0.000 description 1
- GHCKERHPOQWERJ-UHFFFAOYSA-N 3-aminoacridine Chemical compound C1=CC=CC2=NC3=CC(N)=CC=C3C=C21 GHCKERHPOQWERJ-UHFFFAOYSA-N 0.000 description 1
- PBBGSZCBWVPOOL-HDICACEKSA-N 4-[(1r,2s)-1-ethyl-2-(4-hydroxyphenyl)butyl]phenol Chemical class C1([C@H](CC)[C@H](CC)C=2C=CC(O)=CC=2)=CC=C(O)C=C1 PBBGSZCBWVPOOL-HDICACEKSA-N 0.000 description 1
- YGGTVPCTAKYCSQ-UHFFFAOYSA-N 6-methoxyquinolin-8-amine Chemical compound N1=CC=CC2=CC(OC)=CC(N)=C21 YGGTVPCTAKYCSQ-UHFFFAOYSA-N 0.000 description 1
- WREVVZMUNPAPOV-UHFFFAOYSA-N 8-aminoquinoline Chemical compound C1=CN=C2C(N)=CC=CC2=C1 WREVVZMUNPAPOV-UHFFFAOYSA-N 0.000 description 1
- 102100029095 Exportin-1 Human genes 0.000 description 1
- 102100029091 Exportin-2 Human genes 0.000 description 1
- 101710147878 Exportin-2 Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 206010022971 Iron Deficiencies Diseases 0.000 description 1
- 208000009182 Parasitemia Diseases 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 240000003705 Senecio vulgaris Species 0.000 description 1
- 150000001251 acridines Chemical class 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 150000001337 aliphatic alkines Chemical class 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001414 amino alcohols Chemical group 0.000 description 1
- 229940006138 antiglaucoma drug and miotics prostaglandin analogues Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 229940125833 compound 23 Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 125000004427 diamine group Chemical group 0.000 description 1
- 150000001993 dienes Chemical class 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 108700002148 exportin 1 Proteins 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 239000013110 organic ligand Substances 0.000 description 1
- 238000006146 oximation reaction Methods 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 125000003410 quininyl group Chemical group 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- VFJKXAYBWDJZAE-UHFFFAOYSA-N sodium;cyclopenta-1,3-diene;2-(cyclopenta-2,4-diene-1-carbonyl)benzoic acid;iron(2+) Chemical compound [Na+].[Fe+2].C1C=CC=C1.OC(=O)C1=CC=CC=C1C(=O)[C-]1C=CC=C1 VFJKXAYBWDJZAE-UHFFFAOYSA-N 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 210000003812 trophozoite Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
- C07F15/02—Iron compounds
- C07F15/025—Iron compounds without a metal-carbon linkage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
- C07F15/02—Iron compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F17/00—Metallocenes
- C07F17/02—Metallocenes of metals of Groups 8, 9 or 10 of the Periodic System
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9505532A FR2733985B1 (fr) | 1995-05-10 | 1995-05-10 | Complexes organometalliques du fer antipaludiques |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| OA10535A true OA10535A (fr) | 2002-04-26 |
Family
ID=9478836
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| OA70125A OA10535A (fr) | 1995-05-10 | 1997-11-10 | Complexes organométalliques du fer antipaludiques |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US6127543A (da) |
| EP (1) | EP0824536B1 (da) |
| JP (1) | JP4394163B2 (da) |
| AP (1) | AP953A (da) |
| AT (1) | ATE204581T1 (da) |
| AU (1) | AU718946B2 (da) |
| BR (1) | BR9608473A (da) |
| DE (1) | DE69614679T2 (da) |
| DK (1) | DK0824536T3 (da) |
| ES (1) | ES2163022T3 (da) |
| FR (1) | FR2733985B1 (da) |
| OA (1) | OA10535A (da) |
| PT (1) | PT824536E (da) |
| WO (1) | WO1996035698A1 (da) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0205455D0 (en) | 2002-03-07 | 2002-04-24 | Molecular Sensing Plc | Nucleic acid probes, their synthesis and use |
| FR2952823B1 (fr) | 2009-10-30 | 2012-04-20 | Sanofi Aventis | Utilisation de la ferroquine dans le traitement ou la prevention du paludisme |
| FR2951945B1 (fr) | 2009-11-05 | 2013-08-09 | Sanofi Aventis | Composition pharmaceutique |
| FR2961209B1 (fr) * | 2010-06-11 | 2013-03-01 | Sanofi Aventis | Procede de synthese de la ferroquine par amination reductrice convergente. |
| WO2012104204A1 (en) | 2011-01-31 | 2012-08-09 | Vifor (International) Ag | Iron-carbohydrate complex compounds for the intravenous therapy of malaria |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1470210A (en) * | 1974-10-30 | 1977-04-14 | Edwards E | Organometallic derivatives of penicillin |
| DE2815930A1 (de) * | 1978-04-13 | 1979-10-18 | Bayer Ag | Duengemittel zur versorgung von pflanzen mit eisen |
| EP0214933A3 (de) * | 1985-09-03 | 1989-05-24 | Ciba-Geigy Ag | Kombinationspräparate zur Behandlung von Malaria |
-
1995
- 1995-05-10 FR FR9505532A patent/FR2733985B1/fr not_active Expired - Lifetime
-
1996
- 1996-05-10 BR BR9608473-1A patent/BR9608473A/pt not_active IP Right Cessation
- 1996-05-10 PT PT96916196T patent/PT824536E/pt unknown
- 1996-05-10 JP JP53384296A patent/JP4394163B2/ja not_active Expired - Lifetime
- 1996-05-10 AP APAP/P/1997/001141A patent/AP953A/en active
- 1996-05-10 DK DK96916196T patent/DK0824536T3/da active
- 1996-05-10 DE DE69614679T patent/DE69614679T2/de not_active Expired - Lifetime
- 1996-05-10 US US08/952,093 patent/US6127543A/en not_active Expired - Lifetime
- 1996-05-10 AT AT96916196T patent/ATE204581T1/de active
- 1996-05-10 WO PCT/FR1996/000721 patent/WO1996035698A1/fr active IP Right Grant
- 1996-05-10 EP EP96916196A patent/EP0824536B1/fr not_active Expired - Lifetime
- 1996-05-10 ES ES96916196T patent/ES2163022T3/es not_active Expired - Lifetime
- 1996-05-10 AU AU59037/96A patent/AU718946B2/en not_active Expired
-
1997
- 1997-11-10 OA OA70125A patent/OA10535A/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP0824536A1 (fr) | 1998-02-25 |
| AU5903796A (en) | 1996-11-29 |
| JPH11511738A (ja) | 1999-10-12 |
| PT824536E (pt) | 2002-02-28 |
| AU718946B2 (en) | 2000-05-04 |
| ATE204581T1 (de) | 2001-09-15 |
| ES2163022T3 (es) | 2002-01-16 |
| AP9701141A0 (en) | 1998-01-31 |
| BR9608473A (pt) | 1999-11-30 |
| FR2733985B1 (fr) | 1997-07-18 |
| JP4394163B2 (ja) | 2010-01-06 |
| DK0824536T3 (da) | 2001-12-17 |
| DE69614679D1 (de) | 2001-09-27 |
| WO1996035698A1 (fr) | 1996-11-14 |
| DE69614679T2 (de) | 2002-06-27 |
| EP0824536B1 (fr) | 2001-08-22 |
| AP953A (en) | 2001-04-02 |
| FR2733985A1 (fr) | 1996-11-15 |
| US6127543A (en) | 2000-10-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Parhizgar et al. | Introducing new antimalarial analogues of chloroquine and amodiaquine: a narrative review | |
| Jones et al. | Quinine conjugates and quinine analogues as potential antimalarial agents | |
| Salas et al. | Metalloantimalarials | |
| Roux et al. | Ferrocene-based antimalarials | |
| Shreekant et al. | 4-Aminoquinolines: an overview of antimalarial chemotherapy | |
| Kiser et al. | Rational tuning of visual cycle modulator pharmacodynamics | |
| Minori et al. | Comparing the Antileishmanial Activity of Gold (I) and Gold (III) Compounds in L. amazonensis and L. braziliensis in Vitro | |
| CA2605385A1 (fr) | Association entre la ferroquine et l'artesunate pour le traitement du paludisme | |
| WO2020212895A1 (en) | Method and apparatus to facilitate the binding of the gap protein to the mutant ras protein by molecular agents to cure ras-mutation related cancers | |
| Rauf et al. | Antileishmanial, DNA Interaction, and Docking Studies of Some Ferrocene‐Based Heteroleptic Pentavalent Antimonials | |
| Lenz et al. | Taking different roads: l‐Tryptophan as the origin of psilocybe natural products | |
| OA10535A (fr) | Complexes organométalliques du fer antipaludiques | |
| RU2222532C2 (ru) | Соединения ряда бензофуроксана, способ их получения (варианты), фармацевтическая композиция, способ получения парентерального состава и способ лечения коронарных сердечных заболеваний | |
| WO2011001109A1 (fr) | Methodes et compositions pour le traitement de cancers | |
| Ridley et al. | Quinoline antimalarials | |
| Rawe et al. | The cinchona alkaloids and the aminoquinolines | |
| Ukrainets et al. | 4-Hydroxyquinolin-2-ones and their close structural analogues as a new source of highly effective pain-killers | |
| EP0785924B1 (fr) | Bis-2-aminopyridines, leur procede de preparation et leurs applications contre les parasitoses | |
| AU2017204652B2 (en) | Treatment of Type I and Type II diabetes | |
| US20130324598A1 (en) | Treating mycobacterial infection with cu+/++ boosting therapeutics | |
| Boldron et al. | Preparation of Cyclo‐Phen‐Type Ligands: Chelators of Metal Ions as Potential Therapeutic Agents in the Treatment of Neurodegenerative Diseases | |
| EP1469845B1 (fr) | Derives de l'acide haloacetamidobenzoique et leur utilisation pour le traitement de maladies parasitaires | |
| EP0694303A1 (fr) | Utilisation de l'eliprodil et de ses énantiomères pour la préparation de médicaments utiles dans la prévention des neuropathies induites par des agents anticancéreux, e.g. le paclitaxel | |
| FR2986796A1 (fr) | Methodes et compositions pour le traitement du cancer | |
| JP4468638B2 (ja) | インドール骨格を有するアルカロイドを含有するアスコフラノンの抗原虫作用増強剤およびこれらを含む抗原虫作用を有する薬剤組成物 |